# Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

> **NCT02567656** · PHASE1 · COMPLETED · sponsor: **Rhizen Pharmaceuticals SA** · enrollment: 58 (actual)

## Conditions studied

- Lymphoma, T-Cell, Peripheral
- Lymphoma, T-Cell, Cutaneous

## Interventions

- **DRUG:** RP6530

## Key facts

- **NCT ID:** NCT02567656
- **Lead sponsor:** Rhizen Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-03
- **Final completion:** 2018-12-10
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02567656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02567656, "Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02567656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*